| Code | CSB-RA001950MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PMN-310, targeting amyloid precursor protein (APP). APP is a type I transmembrane glycoprotein that plays crucial roles in neuronal development, synaptic plasticity, and cell adhesion. The protein undergoes sequential proteolytic cleavage by β-secretase and γ-secretase enzymes, generating amyloid-beta (Aβ) peptides that aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. Aberrant APP processing and accumulation of Aβ peptides are central to the amyloid cascade hypothesis of neurodegeneration, making APP a critical target for understanding Alzheimer's pathogenesis and related cognitive disorders.
PMN-310 represents an investigational therapeutic antibody designed to target APP and modulate amyloid pathology. This biosimilar antibody provides researchers with a valuable tool for studying APP biology, investigating amyloid-beta production mechanisms, and exploring potential therapeutic interventions in neurodegenerative disease models. It supports investigations into protein processing pathways, neuroinflammation, and synaptic dysfunction associated with Alzheimer's disease and related dementias.
There are currently no reviews for this product.